Overview of the main outcomes in breast-cancer prevention trials
Top Cited Papers
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 361 (9354) , 296-300
- https://doi.org/10.1016/s0140-6736(03)12342-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trialThe Lancet, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Tamoxifen for breast cancer among hysterectomised womenThe Lancet, 2002
- Safety of the Synthetic Retinoid Fenretinide: Long-Term Results From a Controlled Clinical Trial for the Prevention of Contralateral Breast CancerJournal of Clinical Oncology, 2001
- Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE TrialBreast Cancer Research and Treatment, 2001
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 1998
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998